| Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ... The lancet Gastroenterology & hepatology 2 (3), 161-176, 2017 | 2179 | 2017 |
| Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study D Razavi-Shearer, I Gamkrelidze, MH Nguyen, DS Chen, P Van Damme, ... The lancet Gastroenterology & hepatology 3 (6), 383-403, 2018 | 1657 | 2018 |
| Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma JH Lee, JH Lee, YS Lim, JE Yeon, TJ Song, SJ Yu, GY Gwak, KM Kim, ... Gastroenterology 148 (7), 1383-1391. e6, 2015 | 546 | 2015 |
| Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind … M Buti, E Gane, WK Seto, HLY Chan, WL Chuang, T Stepanova, AJ Hui, ... The lancet Gastroenterology & hepatology 1 (3), 196-206, 2016 | 528 | 2016 |
| Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non … HLY Chan, S Fung, WK Seto, WL Chuang, CY Chen, HJ Kim, AJ Hui, ... The lancet Gastroenterology & hepatology 1 (3), 185-195, 2016 | 517 | 2016 |
| Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study S Blach, NA Terrault, F Tacke, I Gamkrelidze, A Craxi, J Tanaka, I Waked, ... The Lancet Gastroenterology & Hepatology 7 (5), 396-415, 2022 | 483 | 2022 |
| Increased risk of adefovir resistance in patients with lamivudine‐resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy YS Lee, DJ Suh, YS Lim, SW Jung, KM Kim, HC Lee, YH Chung, YS Lee, ... Hepatology 43 (6), 1385-1391, 2006 | 438 | 2006 |
| The global impact of hepatic fibrosis and end-stage liver disease YS Lim, WR Kim Clinics in liver disease 12 (4), 733-746, 2008 | 433 | 2008 |
| Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized … SM Yoon, BY Ryoo, SJ Lee, JH Kim, JH Shin, JH An, HC Lee, YS Lim JAMA oncology 4 (5), 661-669, 2018 | 429 | 2018 |
| 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection K Agarwal, M Brunetto, WK Seto, YS Lim, S Fung, P Marcellin, SH Ahn, ... Journal of hepatology 68 (4), 672-681, 2018 | 428 | 2018 |
| HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability GA Kim, YS Lim, J An, D Lee, JH Shim, KM Kim, HC Lee, YH Chung, ... Gut 63 (8), 1325-1332, 2014 | 428 | 2014 |
| Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials SA Harrison, VWS Wong, T Okanoue, N Bzowej, R Vuppalanchi, ... Journal of hepatology 73 (1), 26-39, 2020 | 412 | 2020 |
| Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center JY Lee, KM Kim, SG Lee, E Yu, YS Lim, HC Lee, YH Chung, YS Lee, ... Journal of hepatology 47 (2), 239-244, 2007 | 394 | 2007 |
| Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis JH Shim, HC Lee, KM Kim, YS Lim, YH Chung, YS Lee, DJ Suh Journal of hepatology 52 (2), 176-182, 2010 | 393 | 2010 |
| Association between non-alcoholic fatty liver disease and cancer incidence rate GA Kim, HC Lee, J Choe, MJ Kim, MJ Lee, HS Chang, IY Bae, HK Kim, ... Journal of hepatology 68 (1), 140-146, 2018 | 373 | 2018 |
| MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma SY Kim, J An, YS Lim, S Han, JY Lee, JH Byun, HJ Won, SJ Lee, HC Lee, ... JAMA oncology 3 (4), 456-463, 2017 | 338 | 2017 |
| Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models JH Shim, HC Lee, SO Kim, YM Shin, KM Kim, YS Lim, DJ Suh Radiology 262 (2), 708-718, 2012 | 323 | 2012 |
| Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study J Choi, HJ Kim, J Lee, S Cho, MJ Ko, YS Lim JAMA oncology 5 (1), 30-36, 2019 | 302 | 2019 |
| High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B GA Kim, YS Lim, S Han, J Choi, JH Shim, KM Kim, HC Lee, YS Lee Gut 67 (5), 945-952, 2018 | 294 | 2018 |
| KASL clinical practice guidelines: management of hepatitis C Korean Association for the Study of the Liver (KASL Clinical and molecular hepatology 22 (1), 76, 2016 | 291 | 2016 |
Jonggi ChoiAssistant Professor, Asan Medical Center, University of Ulsan College of MedicineВерификована је имејл адреса на amc.seoul.kr